{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693558",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693558_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"alendronic acid\" outputclass=\"int-drug\">alendronic acid</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"alendronic acid\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/alendronic-acid.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP4656\">alendronic acid</xref></ph> should be taken at least 30 minutes before <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-phosphate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP107980\">calcium phosphate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   alendronic acid .  Manufacturer advises  alendronic acid  should be taken at least 30 minutes before  calcium phosphate .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alendronic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693559",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693559_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">Bendroflumethiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bendroflumethiazide   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693560",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693560_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">Chlorothiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chlorothiazide   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693561",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693561_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">Chlortalidone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chlortalidone   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693562",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693562_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Intravenous</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"digoxin\" outputclass=\"int-drug\">digoxin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Intravenous   calcium phosphate   increases   the concentration of   digoxin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Digoxin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693563",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693563_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dolutegravir\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> should be taken 2 hours before or 6 hours after <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-phosphate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP107980\">calcium phosphate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   dolutegravir .  Manufacturer advises  dolutegravir  should be taken 2 hours before or 6 hours after  calcium phosphate .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dolutegravir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693564",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693564_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"eltrombopag\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/eltrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5928\">eltrombopag</xref></ph> should be taken 2 hours before or 4 hours after <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-phosphate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP107980\">calcium phosphate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   eltrombopag .  Manufacturer advises  eltrombopag  should be taken 2 hours before or 4 hours after  calcium phosphate .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eltrombopag</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693565",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693565_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"estramustine\" outputclass=\"int-drug\">estramustine</ph>. <ph outputclass=\"int-action\">Manufacturer advises separating administration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   estramustine .  Manufacturer advises separating administration .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Estramustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693566",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693566_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">Hydrochlorothiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydrochlorothiazide   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693567",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693567_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">Hydroflumethiazide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydroflumethiazide   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693568",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693568_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"ibandronic acid\" outputclass=\"int-drug\">ibandronic acid</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-phosphate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP107980\">calcium phosphate</xref></ph> for at least 6 hours before or 1 hour after <ph otherprops=\"ibandronic acid\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/ibandronic-acid.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP4671\">ibandronic acid</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   is predicted to   decrease   the absorption of   oral   ibandronic acid .  Manufacturer advises avoid  calcium phosphate  for at least 6 hours before or 1 hour after  ibandronic acid .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibandronic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693569",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693569_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indapamide\" outputclass=\"int-drug\">Indapamide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indapamide   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693570",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693570_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"levothyroxine\" outputclass=\"int-drug\">levothyroxine</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 4 hours</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   is predicted to   decrease   the absorption of   levothyroxine .  Manufacturer advises separate administration by at least 4 hours .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levothyroxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693571",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693571_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"metolazone\" outputclass=\"int-drug\">Metolazone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Metolazone   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693572",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693572_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"risedronate\" outputclass=\"int-drug\">risedronate</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   risedronate .  Manufacturer advises separate administration by at least 2 hours .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Risedronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693573",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693573_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"sodium clodronate\" outputclass=\"int-drug\">sodium clodronate</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/calcium-phosphate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP107980\">calcium phosphate</xref></ph> for 2 hours before or 1 hour after <ph otherprops=\"sodium clodronate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/sodium-clodronate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP4681\">sodium clodronate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   sodium clodronate .  Manufacturer advises avoid  calcium phosphate  for 2 hours before or 1 hour after  sodium clodronate .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium clodronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693574",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693574_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"xipamide\" outputclass=\"int-drug\">Xipamide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hypercalcaemia when given with</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Xipamide   increases   the risk of hypercalcaemia when given with   calcium phosphate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693575",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2#bnf_i1557280693575_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-heading-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"zinc\" outputclass=\"int-drug\">zinc</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   zinc .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zinc</title>"
					}
				}
			],
			"hasSearchLabel": " Calcium phosphate  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/calcium-phosphate-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Calcium phosphate </title>"
			},
			"rdfs:label": "calcium phosphate"
		}
	]
}